Among other things, GSK's CEO Andrew Witty says the British goverment is "systematically delaying" the introduction of new cancer drugs, making "false economies", not buying "the next round of innovation", treating drugs as a "simple procurement business" and in general lacking "any kind of strategic thoughtfulness."
Other than that, he thinks the Government is doing a great job in setting UK drug approval and reimbursement policy. He further implies if GSK keeps losing its abiilty to earn a better return that the UK ministers may face a choice between health budgets and drug industry employment. See PharmaGossip and Pharmalot blogs.
Posted by Bruce Lehr Feb 27th 2012.